Personalized dosing of Immune-Suppressing drug may improve stem cell transplant outcomes
NCT ID NCT05166967
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tested whether giving an individualized dose of antithymocyte globulin (ATG) based on a patient's own drug levels works better than a standard fixed dose. The goal was to reduce graft-versus-host disease (a serious immune reaction) and virus reactivation after a half-matched stem cell transplant. The study enrolled 204 patients and compared survival without these complications between the two dosing groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
antithymocyte globulin (ATG)
What this could lead to
If successful, this could show that tailoring ATG doses reduces serious complications like graft-versus-host disease and viral infections after stem cell transplants.
What could go wrong
This is a completed phase 3 trial, but results are not yet published. The approach may not significantly improve outcomes over standard fixed dosing, and risks like infection or graft failure remain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China